Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Plos One|September 3, 2015
Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized TrialsYunda Huang, Dean Follmann, Martha Nason, et al.
Annals of Internal Medicine|April 28, 2025
High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)Sharon A Riddler, Zoe Moodie, Jesse Clark, et al.
Plos One|August 23, 2011
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)Gavin J Churchyard, Cecilia Morgan, Elizabeth Adams, et al.
Plos One|January 24, 2014
Optimizing viable leukocyte sampling from the female genital tract for clinical trials: an international multi-site studyLyle R McKinnon, Sean M Hughes, Stephen C De Rosa, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 18, 2019
Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US AdultsSara A Healy, Sean C Murphy, Jen C C Hume, et al.
PLOS Global Public Health|April 11, 2025
ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boostLeigh H Fisher, Erica Lazarus, Chenchen Yu, et al.
The Journal of Infectious Diseases|October 18, 2015
Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083Stephen R Walsh, Zoe Moodie, Andrew J Fiore-Gartland, et al.
Plos One|January 31, 2020
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South AfricansLue Ping Zhao, Andrew Fiore-Gartland, Lindsay N Carpp, et al.
Plos Medicine|February 25, 2020
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccinesFatima Laher, Zoe Moodie, Kristen W Cohen, et al.
PLOS Global Public Health|September 20, 2024
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trialVimla Naicker, Fatima Laher, Linda-Gail Bekker, et al.
Pageof 8